Meanwhile, as a prognostic biomarker, DLGAP5 was associated with poor prognosis in colorectal, endometrial, breast, and pancreatic cancers [15, 18, 20, 23]. This evidence concerns the gene DLGAP5 and familial pancreatic carcinoma.